ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

ProQR Therapeutics N.V.NASDAQ: PRQR

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 8.7% from a year ago

Net receivables stood at €2.72M at the end of Q1 FY2026, down 8.7% from a year earlier and down 46.5% from the prior quarter. Over 3 fiscal years it compounded at -55.1% a year.

Context

  • Net receivables amounted to 2.7% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -8.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€2.72M-46.5% QoQ
Last fiscal yearDec 2025
€5.08M+150.8% YoY
Year agoMar 2025
€2.98M-8.7% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.7%——
1 year+150.8%——
3-year CAGR-55.1%——
5-year CAGR——
10-year CAGR——

Net Receivables history

EUR · from the balance sheet

Latest · FY2025
5.08M EUR
Year-over-year change
+150.8%
4-year CAGR
+57.7%

Net Receivables vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -8.7% is the 5th highest of 8, against a peer median of +11.9%.
  • Net receivables amounts to 2.7% of total assets for PRQR, versus a peer median of 0.6%.
PRQR Competitors
Net Receivables for PRQR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VNDAVanda Pharmaceuticals Inc.Mar 2026$56.88M USD+27.5%+17.7%13.1%
IMMPImmutep LimitedDec 2025A$37.52M AUD+2426831.8%-90.4%25.5%
PRQRProQR Therapeutics N.V.Mar 2026€2.72M EUR-8.7%-55.1%2.7%
EDITEditas Medicine, Inc.Mar 2026$2.59M USD+408.2%+43.4%1.7%
TRDAEntrada Therapeutics, Inc.Mar 2026$2.29M USD+11.9%—0.7%
MREOMereo BioPharma Group plcMar 2026$1.88M USD-21.6%—4.6%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$1.34M USD-90.8%+26.3%0.5%
ALLOAllogene Therapeutics, Inc.Mar 2026$1.3M USD——0.3%
ACHVAchieve Life Sciences, Inc.Mar 2026$0 USD——0.0%
CAPRCapricor Therapeutics, Inc.Mar 2026$0 USD-100.0%-52.4%0.0%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
Peer median (excluding PRQR) —+11.9%+17.7%0.6%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents187.52M94.78M131.37M149.41M92.37M
Short-term Investments00000
Net Receivables823K56.25M1.4M2.03M5.08M
Inventory00000
Other Current Assets823K982K02.03M0
Total Current Assets191.48M154.46M133.65M153.85M100.08M
Property, Plant & Equipment (Net)17.47M16.24M18.67M14.11M12.62M
Goodwill00000
Intangible Assets00000
Long-term Investments629K621K000
Tax Assets00000
Other Non-current Assets01000
Total Non-current Assets18.1M16.86M18.67M14.11M12.62M
Total Assets209.58M171.32M152.31M167.96M112.71M
Account Payables191K392K1.7M16K297.87K
Short-term Debt4.77M2.5M1.78M4.58M4.44M
Tax Payables00000
Deferred Revenue0022.72M017.54M
Other Current Liabilities19.87M15.59M11.58M31.26M10.14M
Total Current Liabilities27.6M20.99M37.78M38.9M32.43M
Long-term Debt39.32M4.27M4.74M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0048.79M021.38M
Other Non-current Liabilities14.69M65.57M029.43M0
Total Non-current Liabilities68.75M83.65M68.81M40.5M30.93M
Total Liabilities96.35M104.64M106.59M79.4M63.36M
Common Stock3M3.37M3.72M4.31M4.31M
Retained Earnings(317.77M)(379.11M)(442.8M)(427.16M)(467.31M)
Accumulated OCI30.3M30.26M28.69M27.6M28.68M
Other Stockholders Equity11000
Minority Interest(604K)(384K)000
Total Equity113.23M66.68M45.72M88.56M49.35M
Total Debt60.37M21.97M21.8M17.22M13.99M
Net Debt(127.15M)(72.8M)(109.57M)(132.19M)(78.39M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.